KLRS PE Ratio & Valuation,Is KLRS Overvalued

KLRS Relative Valuation

KLRS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, KLRS is overvalued; if below, it's undervalued.

Historical Valuation

Kalaris Therapeutics Inc (KLRS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.75. The fair price of Kalaris Therapeutics Inc (KLRS) is between -- to -- according to relative valuation methord.

Relative Value

Fair Zone

-----

Current Price：8.72

Fair

-3.50

0.00

EV/EBITDA

Kalaris Therapeutics Inc. (KLRS) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-1.64

EV/EBIT

Kalaris Therapeutics Inc. (KLRS) has a current EV/EBIT of -1.64. The 5-year average EV/EBIT is -0.47. The thresholds are as follows: Strongly Undervalued below -3.88, Undervalued between -3.88 and -2.18, Fairly Valued between 1.23 and -2.18, Overvalued between 1.23 and 2.93, and Strongly Overvalued above 2.93. The current Forward EV/EBIT of -1.64 falls within the Historic Trend Line -Fairly Valued range.

0.00

Kalaris Therapeutics Inc. (KLRS) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.

-4.36

P/OCF

Kalaris Therapeutics Inc. (KLRS) has a current P/OCF of -4.36. The 5-year average P/OCF is -2.02. The thresholds are as follows: Strongly Undervalued below -3.83, Undervalued between -3.83 and -2.92, Fairly Valued between -1.11 and -2.92, Overvalued between -1.11 and -0.21, and Strongly Overvalued above -0.21. The current Forward P/OCF of -4.36 falls within the Strongly Undervalued range.

-4.36

P/FCF

Kalaris Therapeutics Inc. (KLRS) has a current P/FCF of -4.36. The 5-year average P/FCF is -1.31. The thresholds are as follows: Strongly Undervalued below -3.77, Undervalued between -3.77 and -2.54, Fairly Valued between -0.08 and -2.54, Overvalued between -0.08 and 1.14, and Strongly Overvalued above 1.14. The current Forward P/FCF of -4.36 falls within the Strongly Undervalued range.

Kalaris Therapeutics Inc (KLRS) has a current Price-to-Book (P/B) ratio of 3.96. Compared to its 3-year average P/B ratio of 1.27 , the current P/B ratio is approximately 211.92% higher. Relative to its 5-year average P/B ratio of 1.27, the current P/B ratio is about 211.92% higher. Kalaris Therapeutics Inc (KLRS) has a Forward Free Cash Flow (FCF) yield of approximately -23.72%. Compared to its 3-year average FCF yield of -39.99%, the current FCF yield is approximately -40.69% lower. Relative to its 5-year average FCF yield of -39.99% , the current FCF yield is about -40.69% lower.

3.78

P/B

Median3y

1.27

Median5y

1.27

-23.72

FCF Yield

Median3y

-39.99

Median5y

-39.99

Competitors Valuation Multiple

The average P/S ratio for KLRS's competitors is 0.00, providing a benchmark for relative valuation. Kalaris Therapeutics Inc Corp (KLRS) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of KLRS increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of KLRS in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is Kalaris Therapeutics Inc (KLRS) currently overvalued or undervalued?

What is Kalaris Therapeutics Inc (KLRS) fair value?

KLRS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Kalaris Therapeutics Inc (KLRS) is between to according to relative valuation methord.

How does KLRS's valuation metrics compare to the industry average?

What is the current P/B ratio for Kalaris Therapeutics Inc (KLRS) as of Dec 16 2025?

As of Dec 16 2025, Kalaris Therapeutics Inc (KLRS) has a P/B ratio of 3.96. This indicates that the market values KLRS at 3.96 times its book value.

What is the current FCF Yield for Kalaris Therapeutics Inc (KLRS) as of Dec 16 2025?

As of Dec 16 2025, Kalaris Therapeutics Inc (KLRS) has a FCF Yield of -23.72%. This means that for every dollar of Kalaris Therapeutics Inc’s market capitalization, the company generates -23.72 cents in free cash flow.

What is the current Forward P/E ratio for Kalaris Therapeutics Inc (KLRS) as of Dec 16 2025?

As of Dec 16 2025, Kalaris Therapeutics Inc (KLRS) has a Forward P/E ratio of -3.66. This means the market is willing to pay $-3.66 for every dollar of Kalaris Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Kalaris Therapeutics Inc (KLRS) as of Dec 16 2025?

As of Dec 16 2025, Kalaris Therapeutics Inc (KLRS) has a Forward P/S ratio of 0.00. This means the market is valuing KLRS at $0.00 for every dollar of expected revenue over the next 12 months.

KLRS Valuation